stockrow
Friday 6 November 2026
Export AHG’s income statement to Excel — free account
Akso Health Group Sponsored ADR
AHG Healthcare Medical Distribution
Akso Health Group Sponsored ADR’s revenue for fiscal 2026 (year ended March 2026) was $13.8 million, down 6.40% from fiscal 2025.
1.30
0.03
−2.26%
Follow AHG
Alert me
| Older periods | Mar '23 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
0.42 | 1.19 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(4.16) | 99.09 | — | — | |
P/B ratio |
0.94 | 4.50 | — | — | |
Price to Tangible BV |
0.94 | 4.50 | — | — | |
EV/Sales |
1.66 | 1.75 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(2.72) | (2.83) | — | — | |
EV/FCF |
(2.37) | (2.48) | — | — | |
Quick Ratio |
0.00 | 1.30 | 7.50 | 1.41 | |
Current Ratio |
— | 1.46 | 8.19 | 1.53 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 2.18% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.02 | 0.00 | |
Asset Turnover |
0.75 | 0.82 | 0.00 | 0.00 | |
Operating CF/Net income |
0.90 | (0.08) | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | (7.70) | (143.47) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.53 | 0.08 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Graham Net Nets |
1.12 | 0.22 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(86.11%) | (17.14%) | — | — | |
Free Cash Flow Yield |
(165.48%) | (59.06%) | — | — | |
Revenue per Share |
0.06 | 0.04 | — | — | |
Operating CF per Share |
(0.09) | 0.01 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | 0.01 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(1.98) | 0.24 | (4.98) | (174.43) | |
Working Capital |
— | 5.33 | 87.98 | 6.37 | |
Capital Expenditures |
— | — | (0.13) | (175.67) | |
Net Current Asset Value |
(11.62) | 5.33 | 87.92 | 4.66 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
— | 12.83 | 9.34 | 6.21 | |
Average Assets |
26.07 | 24.70 | 131.81 | 116.48 | |
Average Common Equity |
13.00 | 12.44 | 106.47 | 104.11 |
Columns are period end dates · fundamentals updated 26 Oct 2026